Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy

Madhur K. Garg, Samuel Tekyi-Mensah, Sue Bolton, Joaquin Velasco, Edson Pontes, David P. Wood, Arthur T. Porter, Jeffrey D. Forman

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Objectives. To evaluate the relationship between the postprostatectomy prostate-specific antigen (PSA) nadir and the outcome of patients with salvage radiotherapy. Methods. Seventy-eight patients received definitive external beam radiation for recurrence following radical prostatectomy (RP). The PSA nadir was undetectable in 41 patients (less than 0.05 ng/ml). All patients received salvage radiotherapy (median dose 66 Gy) for a median of 19 months (range 2 to 149) following prostatectomy. The median follow-up time was 25 months (range 1 to 59) from the date of completion of radiation. Results. Among patients having an undetectable or detectable postoperative PSA, 78% and 68% were free of disease, respectively, at the last follow-up. At 3 years, the disease-free survival rate were 65% and 60%, respectively (P = 0.6). Overall, the disease-free survival rate at 3 years was 78% in patients with a PSA level 2 ng/ml or less at the time of radiotherapy compared to 31% with a PSA greater than 2 ng/ml (P <0.0001). Conclusions. Many patients who never achieve an undetectable postprostatectomy PSA level may still be salvaged with therapeutic radiotherapy. The best predictor of a favorable outcome is a low (2 ng/ml or less) PSA level at the time of radiation.

Original languageEnglish (US)
Pages (from-to)998-1002
Number of pages5
JournalUrology
Volume51
Issue number6
DOIs
StatePublished - Jun 1998
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Radiotherapy
Radiation
Prostatectomy
Disease-Free Survival
Survival Rate
Recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Garg, M. K., Tekyi-Mensah, S., Bolton, S., Velasco, J., Pontes, E., Wood, D. P., ... Forman, J. D. (1998). Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology, 51(6), 998-1002. https://doi.org/10.1016/S0090-4295(98)00023-5

Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. / Garg, Madhur K.; Tekyi-Mensah, Samuel; Bolton, Sue; Velasco, Joaquin; Pontes, Edson; Wood, David P.; Porter, Arthur T.; Forman, Jeffrey D.

In: Urology, Vol. 51, No. 6, 06.1998, p. 998-1002.

Research output: Contribution to journalArticle

Garg, MK, Tekyi-Mensah, S, Bolton, S, Velasco, J, Pontes, E, Wood, DP, Porter, AT & Forman, JD 1998, 'Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy', Urology, vol. 51, no. 6, pp. 998-1002. https://doi.org/10.1016/S0090-4295(98)00023-5
Garg, Madhur K. ; Tekyi-Mensah, Samuel ; Bolton, Sue ; Velasco, Joaquin ; Pontes, Edson ; Wood, David P. ; Porter, Arthur T. ; Forman, Jeffrey D. / Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. In: Urology. 1998 ; Vol. 51, No. 6. pp. 998-1002.
@article{5a89f92ada8e4df28c6b981f08342e7a,
title = "Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy",
abstract = "Objectives. To evaluate the relationship between the postprostatectomy prostate-specific antigen (PSA) nadir and the outcome of patients with salvage radiotherapy. Methods. Seventy-eight patients received definitive external beam radiation for recurrence following radical prostatectomy (RP). The PSA nadir was undetectable in 41 patients (less than 0.05 ng/ml). All patients received salvage radiotherapy (median dose 66 Gy) for a median of 19 months (range 2 to 149) following prostatectomy. The median follow-up time was 25 months (range 1 to 59) from the date of completion of radiation. Results. Among patients having an undetectable or detectable postoperative PSA, 78{\%} and 68{\%} were free of disease, respectively, at the last follow-up. At 3 years, the disease-free survival rate were 65{\%} and 60{\%}, respectively (P = 0.6). Overall, the disease-free survival rate at 3 years was 78{\%} in patients with a PSA level 2 ng/ml or less at the time of radiotherapy compared to 31{\%} with a PSA greater than 2 ng/ml (P <0.0001). Conclusions. Many patients who never achieve an undetectable postprostatectomy PSA level may still be salvaged with therapeutic radiotherapy. The best predictor of a favorable outcome is a low (2 ng/ml or less) PSA level at the time of radiation.",
author = "Garg, {Madhur K.} and Samuel Tekyi-Mensah and Sue Bolton and Joaquin Velasco and Edson Pontes and Wood, {David P.} and Porter, {Arthur T.} and Forman, {Jeffrey D.}",
year = "1998",
month = "6",
doi = "10.1016/S0090-4295(98)00023-5",
language = "English (US)",
volume = "51",
pages = "998--1002",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy

AU - Garg, Madhur K.

AU - Tekyi-Mensah, Samuel

AU - Bolton, Sue

AU - Velasco, Joaquin

AU - Pontes, Edson

AU - Wood, David P.

AU - Porter, Arthur T.

AU - Forman, Jeffrey D.

PY - 1998/6

Y1 - 1998/6

N2 - Objectives. To evaluate the relationship between the postprostatectomy prostate-specific antigen (PSA) nadir and the outcome of patients with salvage radiotherapy. Methods. Seventy-eight patients received definitive external beam radiation for recurrence following radical prostatectomy (RP). The PSA nadir was undetectable in 41 patients (less than 0.05 ng/ml). All patients received salvage radiotherapy (median dose 66 Gy) for a median of 19 months (range 2 to 149) following prostatectomy. The median follow-up time was 25 months (range 1 to 59) from the date of completion of radiation. Results. Among patients having an undetectable or detectable postoperative PSA, 78% and 68% were free of disease, respectively, at the last follow-up. At 3 years, the disease-free survival rate were 65% and 60%, respectively (P = 0.6). Overall, the disease-free survival rate at 3 years was 78% in patients with a PSA level 2 ng/ml or less at the time of radiotherapy compared to 31% with a PSA greater than 2 ng/ml (P <0.0001). Conclusions. Many patients who never achieve an undetectable postprostatectomy PSA level may still be salvaged with therapeutic radiotherapy. The best predictor of a favorable outcome is a low (2 ng/ml or less) PSA level at the time of radiation.

AB - Objectives. To evaluate the relationship between the postprostatectomy prostate-specific antigen (PSA) nadir and the outcome of patients with salvage radiotherapy. Methods. Seventy-eight patients received definitive external beam radiation for recurrence following radical prostatectomy (RP). The PSA nadir was undetectable in 41 patients (less than 0.05 ng/ml). All patients received salvage radiotherapy (median dose 66 Gy) for a median of 19 months (range 2 to 149) following prostatectomy. The median follow-up time was 25 months (range 1 to 59) from the date of completion of radiation. Results. Among patients having an undetectable or detectable postoperative PSA, 78% and 68% were free of disease, respectively, at the last follow-up. At 3 years, the disease-free survival rate were 65% and 60%, respectively (P = 0.6). Overall, the disease-free survival rate at 3 years was 78% in patients with a PSA level 2 ng/ml or less at the time of radiotherapy compared to 31% with a PSA greater than 2 ng/ml (P <0.0001). Conclusions. Many patients who never achieve an undetectable postprostatectomy PSA level may still be salvaged with therapeutic radiotherapy. The best predictor of a favorable outcome is a low (2 ng/ml or less) PSA level at the time of radiation.

UR - http://www.scopus.com/inward/record.url?scp=0032101133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032101133&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(98)00023-5

DO - 10.1016/S0090-4295(98)00023-5

M3 - Article

C2 - 9609639

AN - SCOPUS:0032101133

VL - 51

SP - 998

EP - 1002

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -